Company Overview and News

 
Macmahon Holdings starts phase II of Batu Hijau mining contract

2018-04-19 proactiveinvestors.com.au
Macmahon Holdings Limited (ASX:MAH) has started phase II of the mining contract for PT Amman Mineral Nusa Tenggara (AMNT) at the Batu Hijau Copper-Gold Project in Indonesia.

 
Board Moves: John Gillam, Kim Horne

2018-03-27 businessnews.com.au
Former Bunnings managing director John Gillam has been named as the incoming chairman of building products company CSR while Macmahon Holdings has bolstered its board by recruiting former Alcoa of Australia executive Kim Horne.

 
LiveHire teams with Macmahon to drive recruitment productivity

2018-02-14 proactiveinvestors.com.au
LiveHire Ltd (ASX:LVH) has successfully implemented and launched its Talent Community recruitment platform for leading mining services provider, Macmahon (ASX:MAH).

 
Goldsworthy, Skira to Power board

2018-01-08 businessnews.com.au
Former Rio Tinto executive Denise Goldsworthy and former Water Corporation chair Eva Skira have been appointed directors of power pole and wire operator Western Power, replacing Northern Australian Infrastructure Facility chair Sharon Warburton and former state politician George Cash.

 
Macmahon appoints new CFO

2017-12-18 businessnews.com.au
Mining contractor Macmahon Holdings has announced that former director Giles Everist has been appointed as the company’s chief financial officer.

 
Macmahon secures $250m contract

2017-12-01 businessnews.com.au
Mining contractor Macmahon Holdings has secured a $250 million open pit mining contract for Dacian Gold’s Mount Morgans gold mine.

 
Dacian Gold lines up Macmahon for $250m Mt Morgans contract

2017-11-30 australianmining.com.au
Macmahon Holdings has received a letter of award for a mining contract worth at least $250 million at Dacian Gold’s Mt Morgans gold operation in Western Australia.

 
NRW wins new work worth $57m

2017-10-20 businessnews.com.au
NRW Holdings has announced it has recently won $57 million worth of contracts through its Action Drill & Blast subsidiary, for work on five coal mines on the east coast.

 
M&A deals take surprise twists

2017-07-17 businessnews.com.au
The possibility of a takeover bid was a regular topic of discussion at Macmahon Holdings’ board meetings during the past year, especially with renowned hostile bidder CIMIC Group sitting on its share register.

 
Macmahon shareholders approve AMNT deal

2017-07-12 businessnews.com.au
Macmahon Holdings chairman Jim Walker said the contract miner would focus on executing its growth plans after shareholders voted overwhelmingly in support of a tie-up with Indonesian company PT Amman Mineral Nusa Tenggara (AMNT).

 
Macmahon Holdings Ltd is the ASX Volume Leader in afternoon trade

2017-07-07 proactiveinvestors.com.au
Proactive Investors is a global leader in financial news, media, research and events focusing on emerging growth companies across four continents.

 
Macmahon Holdings Ltd is the ASX Volume Leader in afternoon trade

2017-07-07 proactiveinvestors.com.au
Proactive Investors is a global leader in financial news, media, research and events focusing on emerging growth companies across four continents.

 
Cimic sells Macmahon stake

2017-07-06 businessnews.com.au
Spanish-controlled CIMIC Group has backed away from its former takeover target Macmahon Holdings, selling its 23.6 per cent stake in the Perth company for $46.8 million.

 
Macmahon Holdings is the ASX Volume Leader in afternoon trade

2017-07-06 proactiveinvestors.com.au
Proactive Investors is a global leader in financial news, media, research and events focusing on emerging growth companies across four continents.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...